Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Effects of combining tumor necrosis factor related apoptosis-inducing ligand with PI3-K-Akt inhibition on nasopharyngeal carcinoma cell].

Li SS, Tang QL, Wang SH, Chen YH, Liu JJ, Wang S, Yang XM.

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Oct;46(10):854-8. Chinese.

PMID:
22321426
2.

Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.

Li SS, Tang QL, Wang SH, Chen YH, Liu JJ, Yang XM.

Tumori. 2011 Nov-Dec;97(6):762-70. doi: 10.1700/1018.11094.

3.

Simultaneously targeting bcl-2 and Akt pathways sensitizes nasopharyngeal carcinoma to tumor necrosis factor-related apoptosis-inducing ligand.

Li SS, Tang QL, Wang SH, Wang S, Yang XM.

Cancer Biother Radiopharm. 2012 Feb;27(1):88-95. doi: 10.1089/cbr.2011.1031. Epub 2011 Sep 21.

PMID:
21936689
5.

Differential response of neuroblastoma cells to TRAIL is independent of PI3K/AKT.

Efron PA, Chen MK, Iyengar M, Dai W, Nagaram A, Beierle EA.

J Pediatr Surg. 2006 Jun;41(6):1072-80.

PMID:
16769337
6.

PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL.

Caravatta L, Sancilio S, di Giacomo V, Rana R, Cataldi A, Di Pietro R.

J Cell Physiol. 2008 Jan;214(1):192-200.

PMID:
17579344
7.

Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway.

Li SS, Yang S, Wang S, Yang XM, Tang QL, Wang SH.

Oncol Rep. 2011 Dec;26(6):1573-9. doi: 10.3892/or.2011.1423. Epub 2011 Aug 17.

PMID:
21850380
8.

Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.

Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.

J Biol Chem. 2001 Oct 19;276(42):38361-9. Epub 2001 Jul 18. Retraction in: J Biol Chem. 2002 Aug 16;277(33):30408.

9.

TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.

Alladina SJ, Song JH, Davidge ST, Hao C, Easton AS.

J Vasc Res. 2005 Jul-Aug;42(4):337-47. Epub 2005 Jun 28.

PMID:
15985761
10.

Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.

Kim S, Kang J, Qiao J, Thomas RP, Evers BM, Chung DH.

J Pediatr Surg. 2004 Apr;39(4):516-21.

PMID:
15065019
13.

Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.

Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.

Oncogene. 2001 Sep 20;20(42):6073-83.

14.

TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.

Lalaoui N, Morlé A, Mérino D, Jacquemin G, Iessi E, Morizot A, Shirley S, Robert B, Solary E, Garrido C, Micheau O.

PLoS One. 2011;6(5):e19679. doi: 10.1371/journal.pone.0019679. Epub 2011 May 20.

15.

Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.

Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI, Bhatia KG.

Clin Cancer Res. 2005 Apr 15;11(8):3102-8.

16.

Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway.

Lane D, Cartier A, Rancourt C, Piché A.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):670-6. Epub 2007 Sep 14.

PMID:
17868340
17.

Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells.

Panka DJ, Mano T, Suhara T, Walsh K, Mier JW.

J Biol Chem. 2001 Mar 9;276(10):6893-6. Epub 2001 Jan 5.

18.

Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.

Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ.

Cancer Res. 2007 Feb 15;67(4):1430-5.

19.

PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.

Tong Y, Zhu W, Huang X, You L, Han X, Yang C, Qian W.

Oncol Rep. 2014 Apr;31(4):1581-8. doi: 10.3892/or.2014.3020. Epub 2014 Feb 11.

PMID:
24535016

Supplemental Content

Support Center